![Kirk Ways](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kirk Ways
Direktor/Vorstandsmitglied bei
SPRUCE BIOSCIENCES, INC.
Vermögen: 73 713 $ am 31.08.2026
Profil
Kirk Ways is Director at Spruce Biosciences, Inc. since 2026.
Former roles include Chief Medical Officer at MBX Biosciences, Inc. from 2023 to 2024, Chief Medical Officer at Nuvelution Pharma, Inc. from 2018 to 2021, Vice Chairman-Department of Internal Medicine at Brody School of Medicine, Chief Development Officer & Vice President at BioStratum, Inc., Head-Cardiovascular & Metabolism at Janssen Pharmaceuticals, Inc., and Principal at Aventis, Inc. Education includes undergraduate studies at Bridgewater College and a doctorate from The University of North Carolina at Chapel Hill.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SPRUCE BIOSCIENCES, INC. 0,04 % | 24.03.2026 | 1 250 ( 0,04 % ) | 73 713 $ | 31.08.2026 |
Aktive Positionen von Kirk Ways
| Unternehmen | Position | Beginn |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Direktor/Vorstandsmitglied | 23.06.2021 |
Ehemalige bekannte Positionen von Kirk Ways
| Unternehmen | Position | Ende |
|---|---|---|
| MBX BIOSCIENCES, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2024 |
Nuvelution Pharma, Inc.
 Nuvelution Pharma, Inc. BiotechnologyHealth Technology Provides solutions for R&D companies in the pharmaceutical and biotech industries | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2021 |
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription drugs | Corporate Officer/Principal | 01.10.2018 |
BioStratum, Inc.
 BioStratum, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products | Corporate Officer/Principal | 05.07.2011 |
Aventis, Inc.
 Aventis, Inc. MiscellaneousMiscellaneous Functions as an investment holding company | Corporate Officer/Principal | - |
Ausbildung von Kirk Ways
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
35
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription drugs | Health Technology |
Aventis, Inc.
Aventis, Inc. MiscellaneousMiscellaneous Functions as an investment holding company | Miscellaneous |
Bridgewater College
 Bridgewater College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioStratum, Inc.
BioStratum, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products | Health Technology |
The University of North Carolina at Chapel Hill
 The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Brody School of Medicine
 Brody School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nuvelution Pharma, Inc.
Nuvelution Pharma, Inc. BiotechnologyHealth Technology Provides solutions for R&D companies in the pharmaceutical and biotech industries | Health Technology |
Spruce Biosciences, Inc.
 Spruce Biosciences, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders | Health Technology |
MBX Biosciences, Inc.
 MBX Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company focused on discovery and development of novel precision peptide therapies for endocrine & metabolic disorders | Health Technology |
